A human study for investigating the effectiveness of Lactobacillus plantarum Q180 on control of triglyceride level

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002085

Enrollment

Registered

2016-09-30

Start date

2016-10-03

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : On the screening visit, subject who voluntarily signs on the written informed consent is reviewed according to inclusion-exclusion criteria. After two-week run-in period, selected

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agrees to participate and sign in informed consent form 2) Man and postmenopausal women (45 years = Age ) 3) Fasting triglyceride level =150mg/dL and <200mg/dL

Exclusion criteria

Exclusion criteria: 1) Recommended Food Score > 36 2) BMI 35 kg/m2 3) high-intensity exercise regularly (=10 hours/week) 4) Chronic smokers (=20cigarettes/day) 5) Alcoholics or drinking quantity: Alcohol 420g/week (soju about 7 bottles/week) 6) follwing disease or personal history hyperlipidemia, diabetes mellitus, hypertension, liver complaint, enteropathy(including ulcerative colitis, lactose intolerance), renal disease, cardiovascular disease, cerebrovascular disease, pancreatitis, cancer, thyroid gland disease, dementia, Parkinson's disease, depressive disorder, anorexia nervosa/polyphagia, multiple sclerosis, Spinal cord injury 7) Volunteer who has taken follwing drug within 1.5 months or during study period : Lipid Lowering Agent(Ursodeoxycholic acid, statin etc), antidiabetics, antibiotics, durg affecting Intestinal Functions, hormone, oral contraception, durg affecting lipid metabolism. 8) Volunteer who has taken herbal medicine within 2 months. 9) Volunteer who has taken probiotics, prebiotics, dietary supplements that affect the body fat, lipid metabolism or intestinal health within 1 months. 10) Volunteer who are hypersensitivity to dietary supplement or ingredients contained in the supplement. 11) Volunteer who has been in clinical demonstration within 3 months. 12) pregnant woman or lactating women 13) Volunteer who judged incongruent by tester through clinical examination center.

Design outcomes

Primary

Measure	Time frame
Lipid Levels and Related metabolic indicators	—

Secondary

Measure	Time frame
gene expression relating lipid metabolism;Anthropometric Measurement ;bowel habits;intestinal health index (stool metabolome(monoenoic fatty acid, indole, phenol, biogenic amines), Harmful/beneficial bacteria identification)	—

Countries

Korea, Republic of

Contacts

Public ContactKIM SEO

Seoul National University of Science and Technology

muckms@naver.com

Outcome results